Argent Trust Co Sells 6,974 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Argent Trust Co decreased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 65.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,745 shares of the medical equipment provider's stock after selling 6,974 shares during the quarter. Argent Trust Co's holdings in Zimmer Biomet were worth $396,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $39,000. OFI Invest Asset Management bought a new position in shares of Zimmer Biomet during the 4th quarter worth about $40,000. SRS Capital Advisors Inc. raised its holdings in shares of Zimmer Biomet by 146.9% in the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after buying an additional 285 shares in the last quarter. Finally, Atala Financial Inc bought a new position in Zimmer Biomet during the 4th quarter valued at about $51,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ZBH. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research note on Monday. JMP Securities reiterated a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Finally, Truist Financial reissued a "hold" rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $124.15.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Up 1.0 %

NYSE:ZBH traded up $0.96 on Friday, hitting $97.90. The stock had a trading volume of 4,367,870 shares, compared to its average volume of 1,650,696. The company has a market cap of $19.37 billion, a PE ratio of 22.00, a P/E/G ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 52 week low of $96.58 and a 52 week high of $123.96. The business's fifty day moving average is $105.95 and its 200 day moving average is $106.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the firm earned $2.20 earnings per share. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.